Clomipramine: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Clomipramine. Educational only — not medical advice.

Reported adverse reactions

ReactionHighest frequency reported*
Dry mouth84%
Somnolence54%
Tremor54%
Dizziness54%
Headache52%
Constipation47%
Ejaculation failure42%
Fatigue39%
Nausea33%
Increased sweating29%
Insomnia25%
Dyspepsia22%
Anorexia22%
Libido change21%
Impotence20%
Nervousness18%
Weight increase18%
Abnormal vision18%
Abdominal pain16%
Pharyngitis14%

*Highest percentage across placebo-controlled trial tables summarized in current labeling.

Labeled uses

Clomipramine hydrochloride capsules USP are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. The effectiveness of clomipramine hydrochloride capsules for the treatment of OCD was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. Patients in all studies had moderate-to-severe OCD (DSM-III), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH-OC). Patients t…

Source: FDA labeling via NIH DailyMed (set 7a2d0cf1…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.